Valuation: Edesa Biotech, Inc.

Market Cap 55.94M 48.78M 46.06M 41.82M 78.36M 5.37B 78.69M 552M 213M 2.73B 210M 205M 8.78B P/E 2026 *
-2.08x
P/E 2027 * -2x
Enterprise Value 55.94M 48.78M 46.06M 41.82M 78.36M 5.37B 78.69M 552M 213M 2.73B 210M 205M 8.78B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.5%
Yield 2026 *
-
Yield 2027 * -
1 week-2.13%
Current month-12.57%
1 month-27.50%
3 months-43.67%
6 months-46.16%
Current year+191.55%
1 week 3.84
Extreme 3.8395
4.44
1 month 3.84
Extreme 3.8395
6
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
84
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 01/08/2015
Director of Finance/CFO 57 01/05/2025
President 48 07/06/2019
Director TitleAgeSince
Chairman 50 07/06/2019
Director/Board Member 55 07/06/2019
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap. Importance
1/9/26 Free

Founder

5,714 0.0593%
3/8/26 Free

Founder

5,324 0.0553%
2/7/26 Free

Founder

3,378 0.0380%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.13%+80.00%-32.02% 55.94M
-0.31%+5.79%+48.93%+97.53% 70.88B
+0.39%+2.06%+40.91%+78.49% 62.49B
-3.21%-7.27%-17.73%+351.98% 26.21B
+0.50%+7.13%+29.43%+15.48% 26.34B
-2.64%-0.69%-0.26%-11.90% 24.13B
+0.71%+8.03%+27.22%-13.18% 20.72B
-1.26%-7.81%+169.33%+302.38% 15.36B
-0.22%+3.99%+44.28%+173.35% 14.46B
+0.73%+1.71%-7.18%+886.19% 14.25B
Average -0.53%+1.27%+41.49%+184.83% 27.49B
Weighted average by Cap. -0.47%+1.44%+36.51%+147.94%

Financials

2026 *2027 *
Net sales - -
Net income -17.52M -15.28M -14.43M -13.1M -24.55M -1.68B -24.65M -173M -66.7M -855M -65.83M -64.37M -2.75B -29.25M -25.51M -24.09M -21.87M -40.98M -2.81B -41.15M -289M -111M -1.43B -110M -107M -4.59B
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
-
Date Price Change Volume
18/09/26 US$4.140 0.00% 41,397
17/09/26 US$4.140 +6.98% 24,799
16/09/26 US$3.870 -6.07% 94,424
15/09/26 US$4.120 -0.36% 35,009
14/09/26 US$4.135 -2.25% 54,247
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.140USD
Average target price
16.33USD
Spread / Average Target
+294.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!